We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ - Free Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters, with an average positive surprise of 3.09%. Estimate movement has been stable over the past 7 days.
Currently, JNJ has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: JNJ beat on first quarter earnings - the company reported EPS of $2.06 while our consensus called for EPS of $2.01.
Revenues Beat: Revenues also slightly beat expectations. Johnson & Johnson posted revenues of $20.0 billion, compared to our consensus estimate of $19.48 billion.
Key Statistics: Pharmaceutical segment sales rose 19.4% year over year to $9.84 billion, reflecting 15.1% operational growth and 4.3% positive currency impact as sales rose in both domestic and international markets.
Ups 2018 Sales Outlook: J&J maintained the previously issued earnings guidance for 2018 while increasing the sales range.
J&J still expects 2018 adjusted earnings per share in the range of $8.00 - $8.20, reflecting an operational growth rate between 6.8% and 9.6%.
However, it expects revenues in the range of $81.0 to $81.8 billion higher than $80.6 billion to $81.4 billion expected previously, reflecting operational constant currency sales growth rate in the range of 4.0% to 5.0% (previously 3.5% to 4.5%).
The Zacks Consensus Estimate for earnings per share and revenues were $8.11 and $81.27 billion, respectively.
Stock Price Impact: Shares rose 1.3% in pre-market trading.
Check back later for our full write up on this JNJ earnings report later!
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 ""Strong Buys"" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 ""Strong Sells."" Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
J&J (JNJ) Beats on Q1 Earnings & Sales, Ups 2018 Sales View
Johnson & Johnson (JNJ - Free Report) , the bellwether of healthcare companies, has a strong presence in the pharmaceutical, medical devices and consumer care markets across the world. This New Jersey-based company is well known for its baby-care products and brands like Tylenol in addition to drugs like Remicade and Concerta.
However, like many of its peers, JNJ is facing generic competition and pricing pressure for some of the products in its pharmaceutical segment.
In this scenario, investor focus remains on late-stage pipeline candidates and their commercial potential as well as the performance of new products apart from the usual top-and bottom-line numbers.
JNJ has a pretty good earnings track record with the company delivering positive earnings surprises in each of the last four quarters, with an average positive surprise of 3.09%. Estimate movement has been stable over the past 7 days.
Currently, JNJ has a Zacks Rank #3 (Hold), but that could definitely change following the company’s earnings report which was just released. We have highlighted some of the key stats from this just-revealed announcement below:
Earnings Beat: JNJ beat on first quarter earnings - the company reported EPS of $2.06 while our consensus called for EPS of $2.01.
Revenues Beat: Revenues also slightly beat expectations. Johnson & Johnson posted revenues of $20.0 billion, compared to our consensus estimate of $19.48 billion.
Key Statistics: Pharmaceutical segment sales rose 19.4% year over year to $9.84 billion, reflecting 15.1% operational growth and 4.3% positive currency impact as sales rose in both domestic and international markets.
Ups 2018 Sales Outlook: J&J maintained the previously issued earnings guidance for 2018 while increasing the sales range.
J&J still expects 2018 adjusted earnings per share in the range of $8.00 - $8.20, reflecting an operational growth rate between 6.8% and 9.6%.
However, it expects revenues in the range of $81.0 to $81.8 billion higher than $80.6 billion to $81.4 billion expected previously, reflecting operational constant currency sales growth rate in the range of 4.0% to 5.0% (previously 3.5% to 4.5%).
The Zacks Consensus Estimate for earnings per share and revenues were $8.11 and $81.27 billion, respectively.
Stock Price Impact: Shares rose 1.3% in pre-market trading.
Johnson & Johnson Price and EPS Surprise
Johnson & Johnson Price and EPS Surprise | Johnson & Johnson Quote
Check back later for our full write up on this JNJ earnings report later!
The Best & Worst of Zacks
Today you are invited to download the full, up-to-the-minute list of 220 Zacks Rank #1 ""Strong Buys"" free of charge. From 1988 through 2015 this list has averaged a stellar gain of +25% per year. Plus, you may download 220 Zacks Rank #5 ""Strong Sells."" Even though this list holds many stocks that seem to be solid, it has historically performed 6X worse than the market. See these critical buys and sells free >>